An official website of the United States government

General Description

Type 1 Diabetes TrialNet (TrialNet) is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. TrialNet was established in response to the Surgeon General's Report Healthy People 2000. This report identified diabetes as a national health objective for the Nation. In response to the report, Congress created the Diabetes Research Working Group (DRWG) to develop a plan for diabetes research. One recommendation of the DRWG was to conduct additional research studies (clinical trials) to prevent type 1 diabetes.

Related Studies

Related Studies Table
Acronym
Name
TN00TN00 DPT-1 Follow-up
TN01TrialNet Pathway To Prevention (formerly Natural History Study)
TN02Preservation of Pancreatic Production of Insulin Through Immunosuppression
TN03Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials
TN04TrialNet - TN04 T cell assay validation
TN05The Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects
TN06TrialNet 06: Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Pilot Trial
TN07Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
TN08TrialNet 08: Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-alum) on the Progression of Type 1 Diabetes in New Onset Subjects
TN09TrialNet 09: Effects of CTLA-4 IG (Abatacept) on the Progression of Type 1 Diabetes in New Onset Subjects
TN10Anti-CD3 Mab (Teplizumab) for Prevention of Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus
TN12Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes
TN14TrialNet 14: Effects of Canakinumab on the Progression of Type 1 Diabetes in New Onset Subjects
TN16Long-Term Investigative Follow-Up in TrialNet Study
TN18TrialNet 18 -CTLA-4 Ig (Abatacept) for Prevention of abnormal glocose tolerance and diabetes in relatives at-risk for Type 1 Diabetes Mellitus
TN19Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes
TN20Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus
TN22Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
TN27TOPPLE T1D: A Multiple Ascending Dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of NNC0361-0041 Administered Subcutaneously to Patients with Type 1 Diabetes Mellitus
Publications
Explore publications resulting from the use of study resource
View publications (8)